<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959373</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00802-43</org_study_id>
    <secondary_id>2013-22</secondary_id>
    <nct_id>NCT01959373</nct_id>
  </id_info>
  <brief_title>Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is characterized clinically by abnormalities of both&#xD;
      upper motor neurons (UMN) and lower motor neurons (LMN). The presence of UMN signs is not&#xD;
      always easy to establish. The only technique used in routine to assess the corticospinal&#xD;
      dysfunctions is based on transcranial magnetic stimulation (TMS). However, this technique is&#xD;
      largely dependent on LMN state and is based on artificial motor cortex activation.&#xD;
&#xD;
      The main objective of our study project is to evaluate a new method assessing functional&#xD;
      changes in motor system in ALS patients. By using cortico-muscular and cortico-cortical&#xD;
      coherences, it could be possible to show modifications in both cortico-muscular relationship&#xD;
      and in cortical activity coordination which could be related to clinical state in ALS&#xD;
      patients. We notably expect a decrease in cortico-muscular coherence in ALS patients.&#xD;
      Furthermore, these analyses could provide new insights in motor system plasticity phenomena.&#xD;
      We expect a partial covering of voluntary motor command by cortical areas adjacent to primary&#xD;
      motor cortex. Lastly, the hypothesis that an increased proportion of voluntary motor control&#xD;
      may be assumed by ipsilateral corticospinal tract could be tested by coherence analyses.&#xD;
&#xD;
      Coherence analysis might be a useful method to detect corticospinal tract dysfunctions. This&#xD;
      method has the advantage to be painless and not to use artificial stimulations as it is used&#xD;
      in TMS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recording neuronal activities</measure>
    <time_frame>12 months</time_frame>
    <description>simultaneous recording of brain activity using electrodes attached to the scalp and muscle activities of muscles of the hands with electrodes bonded to the skin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>identify plasticity phenomena</measure>
    <time_frame>12 months</time_frame>
    <description>identify plasticity phenomena used in the cortex during the disease. The question is whether a reorganization of cortical networks could preserve, temporarily, the ability of patients to perform muscle contractions which case to determine the nature of the changes induced</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>electroencephalograms (EEG)</intervention_name>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>electro-myography (EMG)</intervention_name>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient female or male, more than 18 years,&#xD;
&#xD;
          -  Patien with a diagnosis of amyotrophic lateral sclerosis according to the El Escorial&#xD;
             criteria of Brooks et al. 1994&#xD;
&#xD;
          -  Patient , the beginning of the SLA date less than 12 months,&#xD;
&#xD;
          -  Patient not having a familial form of ALS,&#xD;
&#xD;
          -  Patient not having cancer, autoimmune disease, liver failure, severe hypertension or&#xD;
             untreated, severe conduction disorders or uncontrolled arrhythmia&#xD;
&#xD;
          -  Patient not having a chronic psychiatric disease, dementia.&#xD;
&#xD;
          -  Patient with normal visual function&#xD;
&#xD;
          -  Patients receiving social coverage&#xD;
&#xD;
          -  Patient have read, understood and signed an informed consent after information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient minor&#xD;
&#xD;
          -  Patient with a familial form of ALS,&#xD;
&#xD;
          -  Patient associated with severe progressive disease (cancer, autoimmune disease , liver&#xD;
             failure )&#xD;
&#xD;
          -  Patient (s) with chronic mental illness, dementia ,&#xD;
&#xD;
          -  Presence of atypical clinical signs such as cerebellar ataxia , extrapyramidal signs,&#xD;
             sensory disorders , autonomic dysfunction .&#xD;
&#xD;
          -  Clinical signs of chronic respiratory failure or slow and / or forced less than 70% of&#xD;
             the theoretical value or chronic hypercapnia than 45 mmHg vital capacity .&#xD;
&#xD;
          -  Patient private freedom following a judicial or administrative decision&#xD;
&#xD;
          -  Patient major Trust&#xD;
&#xD;
          -  Pateinte pregnant, parturient , lactating&#xD;
&#xD;
          -  Patient major in legal protection ( guardianship )&#xD;
&#xD;
          -  Pateinte pregnant , parturient , lactating&#xD;
&#xD;
          -  Patient hospital without consent&#xD;
&#xD;
          -  Patient admitted in a health or social establishment for purposes other than research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

